Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.66 |
| ▸ | CTSK | P43235 | 12/20 | 0.66 |
| ▸ | CTSB | P07858 | 6/20 | 0.66 |
| ▸ | CTSL | P07711 | 4/20 | 0.66 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6019868 | 1.00 | CTSS (0.66) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6020997 | 0.90 | CTSS (0.65) | CTSSCTSKCTSBCTSL | |
| SCHEMBL6020647 | 0.88 | CTSS (0.58) | CTSSCTSKCTSBCTSL | |
| SCHEMBL6019874 | 0.87 | CTSS (0.68) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6020645 | 0.87 | CTSS (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6020580 | 0.86 | CTSL (0.61) | CTSSCTSKCTSBCTSL | |
| SCHEMBL12445413 | 0.85 | CTSS (0.74) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL5873366 | 0.84 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6020216 | 0.84 | CTSK (0.60) | CTSSCTSKCTSBCTSL | |
| SCHEMBL6019089 | 0.84 | CTSL (0.59) | CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | THE PROCTER & GAMBLE COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | MPO, SERPINB1, NCF1 | CTSS 144/4885CTSK 210/4885CTSB 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.